<tt id="qegqq"></tt>
<tt id="qegqq"></tt>
<tt id="qegqq"></tt>
<tt id="qegqq"></tt>
<tt id="qegqq"></tt>
<tt id="qegqq"></tt>

中文

公司新聞

當前位置: 首頁 > 新聞動態 > 公司新聞

領晟醫療新靶點抗腫瘤藥物LH031一期臨床研究首例受試者入組給藥!

2019-05-31

 

    5月31日,廣州領晟醫療的抗腫瘤新藥LH031的I期臨床試驗順利完成首例受試者入組給藥。口服LH031擬在血液腫瘤以及實體腫瘤等幾個意向性適應癥上進行劑量以及安全性的探索。LH031為全球首個口服給藥的EG5抑制劑,在臨床前模型上表現出顯著的腫瘤抑制作用,而口服給藥具有注射EG5抑制劑無法比擬的優勢以及明顯的靶向優勢。 LH031目前擬開發的適應癥包括多發性骨髓瘤,乳腺癌,腦膠質瘤等等。該研究計劃在廣州中山大學腫瘤防治中心完成。


      May 31, Link Health Group successfully complete the first dosing for the first patient in PI study of LH031. LH031 is an innovative drug shows significant anti-cancer efficacy on animal models based on its inhibition of EG5. LH031 is the fist and also the best-in-class EG5 inhibitor to be planned to test on several cancers like MM, Breast cancer, GBM, etc. Several previous studies have been done and published before on those indications. The studies include dosage escalation and safety evaluation, which will be done in Sun Yat-sen University Cancer Center in Guangzhou.


零投入网上赚钱 456| 78| 429| 768| 510| 627| 882| 33| 900| 498| 951| 687| 351| 870| 594| 384| 312| 306| 201| 774| 177| 987| 864| 603| 723| 975| 918| 132| 207| 39| 9| 807| 738| 144| 141| 309|